Biopharmaceutical Scientists specialize in the development and production of biologically-based medicines, including therapeutic proteins, antibodies, and vaccines, derived from living organisms. Their work involves understanding the molecular mechanisms of diseases and designing biologics that can interact with the body to treat or prevent them. These scientists work with complex biologic molecules, ensuring they are stable, effective, and safe for human use. From early-stage discovery to large-scale manufacturing, biopharmaceutical scientists employ advanced techniques like recombinant DNA technology, cell culture, and protein engineering to develop new treatments. Their expertise is essential in the development of innovative therapies for conditions that are difficult to treat with traditional pharmaceuticals, such as autoimmune diseases and cancer.
Biopharmaceutical scientists are also responsible for optimizing production processes and ensuring regulatory compliance. They collaborate with regulatory agencies, quality control teams, and manufacturing experts to scale up production and ensure that products meet strict safety and efficacy standards. As biologic therapies become increasingly common, these scientists are pushing the boundaries of medicine by developing personalized and targeted treatments that offer more precise and effective solutions for patients. Their research continues to be pivotal in shaping the future of healthcare, offering hope for patients with conditions that previously had limited treatment options. With the rise of biologics, biopharmaceutical scientists are at the forefront of modern medicine, driving breakthroughs that will impact global healthcare for years to come.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia